- Entry
- $2.58
- Final
- $1.16 -55.1%
- Target
- —
- Score
- -1.00
Ticker: REVB (Revelation Biosciences) Sector: Biotech / Renal Health Current Price (PM): \~$1.18 (+38% spike) The Catalyst: Why is it moving? Revelation Biosciences just dropped a massive PR announcing they have reached an agreement with the FDA on a simplified approval pathway for their lead candidate, Gemini, for treating Acute Kidney Injury (AKI). The Key Takeaways from today's PR: • Single Study NDA: The FDA agreed that a single adaptive Phase 2/3 study (approx. 300 patients) is sufficient for a …
— ORIGINAL POST ·
$REVB: Major FDA Win: Single Study Pathway for Gemini (AKI) Approved 🚀
· r/Shortsqueeze
· Jan 23, 2026